Pancreatic cancer is the fourth leading cause of cancer deaths. Less than 20% of patients are candidates for surgery at diagnosis. There are few available treatment options for those patients not eligible for surgery, and so most survive for only a few months. These needs are driving our research and clinical focus at Cambridge. Scientists are involved in research into the biology of pancreatic cancer, identification of biomarkers, epidemiological studies and clinical trials with the mission of improving the outcome for patients with this disease.
Data integration techniques are being explored in the prospective clinical trial ATRiUM (CI: Professor Duncan Jodrell).
Further information on the CRUK Cambridge Centre Pancreatic Cancer Programme.
The Mark Foundation Institute for Integrated Cancer Medicine (MFICM) at the University of Cambridge aims to revolutionise cancer care by affecting patients along their treatment pathway.
